Skip to Main Content

Author Details

David M Weinstock
Merck & Co.
1998
179
60
PMIDPaper TitleJournal TitlePublished Year
37379367Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.Sci Transl Med2023
37774696Genetically informed therapy for lymphoma: the discomfiting benefit of lumping splits.Cancer Cell2023
37732189Leukemia circulation kinetics revealed through blood exchange method.bioRxiv2023
37643767Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1.Mol Cancer Ther2023
37729434TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence.Sci Transl Med2023
37723306PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma.Nat Cancer2023
37290440New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.Cell Chem Biol2023
37286545Integrated multi-omics analyses reveal homology-directed repair pathway as a unique dependency in near-haploid leukemia.Blood Cancer J2023
37015223ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas.Cell Chem Biol2023
34615655Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.Cancer Discov2022
35247900Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma.Blood Cancer Discov2022
34936696Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.Blood2022
34967008The molecular ontogeny of follicular lymphoma: gene mutations succeeding the BCL2 translocation define common precursor cells.Br J Haematol2022
33247204RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia.Oncogene2021
33712811Author Correction: IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells.Nature2021
33560380Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features.Blood Adv2021
34432866Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway.Blood2021
34653242A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.Blood2021
33988700Low-cost transcriptional diagnostic to accurately categorize lymphomas in low- and middle-income countries.Blood Adv2021
34151238Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia.iScience2021
32560455A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries.Cancers (Basel)2020
31699827AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells.Clin Cancer Res2020
31961925Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions.Blood2020
33217342Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.Cancer Cell2020
33077594Polymerase δ promotes chromosomal rearrangements and imprecise double-strand break repair.Proc Natl Acad Sci U S A2020
33149299IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells.Nature2020
32677976DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.J Hematol Oncol2020
32699415Signalling input from divergent pathways subverts B cell transformation.Nature2020
32183945Breaking Down the Barriers to Define and Treat NK/T Cell Lymphoma.Cancer Cell2020
32330423Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma.Cell Rep2020
32232478Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma.Blood Adv2020
30545835Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.Blood2019
31698426TFH lymphomas: the times they aza-changin'?Blood2019
31748664Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models.Sci Rep2019
31721781Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia.PLoS One2019
31439577Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.Clin Cancer Res2019
31437130DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.J Clin Invest2019
31383641Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas.Blood2019
31203830Chemical, Biological, Radiological, Nuclear, and Explosive (CBRNE) Science and the CBRNE Science Medical Operations Science Support Expert (CMOSSE).Disaster Med Public Health Prep2019
31068700Next-generation characterization of the Cancer Cell Line Encyclopedia.Nature2019
31040105Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents.Cancer Discov2019
30498064Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.Blood2019
29196080Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.Biol Blood Marrow Transplant2018
30213852Parp3 promotes long-range end joining in murine cells.Proc Natl Acad Sci U S A2018
30126979Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles.Blood2018
30020951Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility.PLoS One2018
29857068Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.J Invest Dermatol2018
30089630Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.Blood2018
30504292Challenges and implications of genomics for T-cell lymphomas.Hematology Am Soc Hematol Educ Program2018
29675955Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.Br J Haematol2018
  • 1 - 50 of 179

Recommended Authors

Zhengming Chen
Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 2013
Number of shared co-authors 5
Srinivas K Tantravahi
Huntsman Cancer Institute at the University of Utah.
Career Start Year 2012
Number of shared co-authors 5
Gareth P Gregory
School of Clinical Sciences at Monash Health, Monash University
Career Start Year 2011
Number of shared co-authors 10
Milos D Miljkovic
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2009
Number of shared co-authors 1
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 1
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Career Start Year 2009
Number of shared co-authors 13
Kara L Davis
Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 5
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 1
Aarthi Shenoy
MedStar Washington Hospital Center
Career Start Year 2006
Number of shared co-authors 0
Julia Carnevale
University of California san francisco
Career Start Year 2006
Number of shared co-authors 5
Linghua Wang
The University of Texas M. D. Anderson
Career Start Year 2006
Number of shared co-authors 11
Christopher C Porter
Emory University School of Medicine
Career Start Year 2003
Number of shared co-authors 3
Susan Geyer
Division of Clinical Trials and Biostatistics, Mayo Clinic
Career Start Year 2001
Number of shared co-authors 7
Pingfu Fu
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 2
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 0
Eric Tse
School of Clinical Medicine, University of Hong Kong
Career Start Year 1997
Number of shared co-authors 2
Changchun Deng
Center for Lymphoid Malignancies, Columbia University Medical Center
Career Start Year 1997
Number of shared co-authors 0
Yongjin Li
Mayo Clinic
Career Start Year 1995
Number of shared co-authors 10
Arndt Borkhardt
Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf
Career Start Year 1992
Number of shared co-authors 10
Bijal Shah
Moffitt Cancer Center
Career Start Year 1992
Number of shared co-authors 7
Christopher D Gocke
Johns Hopkins University School of Medicine
Career Start Year 1992
Number of shared co-authors 3
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 10
Geoffrey Neale
St. Jude Children's Research Hospital
Career Start Year 1989
Number of shared co-authors 9
Suzanne Kamel-Reid
Toronto General Hospital, University Health Network, University of Toronto
Career Start Year 1988
Number of shared co-authors 2
Mark Lawler
Queens University Belfast Belfast
Career Start Year 1988
Number of shared co-authors 8
Kim E Nichols
St. Jude Children's Research Hospital
Career Start Year 1986
Number of shared co-authors 13
Phuong Nguyen
Hoag Memorial Hospital Presbyterian
Career Start Year 1983
Number of shared co-authors 9
Paul Brent Ferrell
Vanderbilt University
Career Start Year 1981
Number of shared co-authors 2
Ulrich D??hrsen
University Hospital Essen, University of Duisburg-Essen
Career Start Year 1979
Number of shared co-authors 4
Stephen E Kurtz
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 1979
Number of shared co-authors 4

Collaborators

Amanda L Christie
Dana-Farber Cancer Institute
Co-authored papers 16
Mark A Murakami
Dana-Farber Cancer Institute
Co-authored papers 10
Giorgio Inghirami
Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
Co-authored papers 9
John L Hick
University of Minnesota
Co-authored papers 8
Daniel J DeAngelo
Dana-Farber Cancer Institute
Co-authored papers 7
Donna Neuberg
Co-authored papers 7
Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 7
Kimberly Stegmaier
Dana-Farber Cancer Institute
Co-authored papers 6
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 5
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Co-authored papers 5
Alex Look
Dana-Farber Cancer Institute
Co-authored papers 5
David M Dorfman
Brigham and Women's Hospital and Harvard Medical School
Co-authored papers 5
Mahmoud Ghandi
Co-authored papers 5
James E Bradner
Co-authored papers 4
David E Root
Broad Institute of Harvard and MIT
Co-authored papers 4
Aaron R Thorner
Co-authored papers 4
Benjamin L Ebert
Co-authored papers 4
Paul Van Hummelen
Co-authored papers 4
Akhilesh Pandey
Co-authored papers 4
Timothy J Sullivan
Co-authored papers 4
Erika Brunet
INSERM UMR 3, Imagine Institute
Co-authored papers 3
Michael J Kluk
Co-authored papers 3
David P Steensma
Novartis Institutes for BioMedical Research
Co-authored papers 3
Robin Fo??
Sapienza University.
Co-authored papers 3
Arun P Wiita
University of California San Francisco
Co-authored papers 3
Alicia A Livinski
National Institutes of Health Library
Co-authored papers 3
Anna C Schinzel
Co-authored papers 3
Alan D D'Andrea
Dana-Farber Cancer Institute
Co-authored papers 3
Dipanjan Chowdhury
Dana-Farber Cancer Institute
Co-authored papers 3
Myles Brown
Co-authored papers 3
Release 1.2